Coadministration of acetaminophen and troglitazone: Pharmacokinetics and safety

Journal of Clinical Pharmacology

Volumn 38, Issue 9, 1998, Pages 819-824

  Young, Malcolm A ^a   Lettis, Sally ^a   Eastmond, Richard ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTE NUCLEAR TRANSCRIPTION FACTOR; DRUG METABOLITE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PARACETAMOL; PARACETAMOL GLUCURONIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; TROGLITAZONE; TROGLITAZONE QUINONE; TROGLITAZONE SULFATE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CROSS REACTIVITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG URINE LEVEL; FOOD DRUG INTERACTION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ACETAMINOPHEN; ADMINISTRATION, ORAL; ADULT; ANALGESICS, NON-NARCOTIC; CHROMANS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031689117     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Fujiwara T, Yoshioka T, Ushiyama I, Horikoshi H: Characterisation of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988;37:1549-1558.
2. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H: Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-bd/db mice. Metabolism 1995;44:486-490.
3. Horikoshi H, Fujiwara T, Yoshioka S, Wada M, Fukami M: Pharmacological characteristics of new antidiabetic agent CS-045 in diabetic animals. In, Shafrir H (ed.): Frontiers in Diabetes Research: Lessons from Animal Diabetes III. Volume 8. London: Smith-Gordon, 1990;320-324.
4. Ciaraldi T, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990;39:1056-1062.
5. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM Kliewer S: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ. J Biol Chem 1995;270:12953-12956.
6. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, et al: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996;39:701-709.
7. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycaemic agent CS-045 in type 2 diabetes. Diabetes Care 1992;15:193-203.
8. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effects of troglitazone: a new hypoglycaemic agent in patients with type 2 diabetes poorly controlled by diet therapy. Diabetes Care 1996;19:151-156.
9. Young MA, Lettis S, Eastmond R: Concomitant administration of cholestyramine influences the absorption of troglitazone. Br J Clin Pharmacol 1998;45:37-40.
10. Young MA, Lettis S, Eastmond R: Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food. Br J Clin Pharmacol 1998;45:31-35.
11. Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. New Engl J Med 1998;338:916-917.
12. Blackledge HM, O'Farrell J, Minton NA, McLean AEM: The effect of therapeutic doses of acetaminophen on sulphur metabolism in man. Hum Exp Toxicol 1991;10:159-165.
13. Park KB, Pirmohamed M, Kitteringham NR: The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995;68:385-424.
14. Ameer B, Greenblatt DJ, Divoll M, Abernethy DR, Shargel L: High-performance liquid Chromatographic determination of acetaminophen in plasma: single-dose pharmacokinetic studies. J Chromatogr 1981;226:224-230.
15. Pabst G, Jaeger H: Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 1990; 38:5-10.
16. Conover WJ: Practical Nonparametric Statistics. Second edition. New York: Wiley, 1980.